# Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus

> **NCT00787605** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 860 (actual)

## Conditions studied

- Hypertension
- Diabetes Mellitus

## Interventions

- **DRUG:** Amlodipine
- **DRUG:** Hydrochlorothiazide (HCTZ)
- **DRUG:** Aliskiren

## Key facts

- **NCT ID:** NCT00787605
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 860 (ACTUAL)
- **Last updated:** 2016-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00787605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00787605, "Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT00787605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*